Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer

NCT00054873 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2006-07-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of tezacitabine when given alone or in combination with 5-fluorouracil (5-FU) to subjects who have advanced esophageal or gastric adenocarcinoma.

Conditions

  • Esophageal Neoplasms
  • Stomach Neoplasms
  • Adenocarcinoma

Interventions

DRUG

tezacitabine

Sponsors & Collaborators

  • Chiron Corporation

    lead INDUSTRY

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Completion
2004-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00054873 on ClinicalTrials.gov